JP2010515748A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010515748A5 JP2010515748A5 JP2009545662A JP2009545662A JP2010515748A5 JP 2010515748 A5 JP2010515748 A5 JP 2010515748A5 JP 2009545662 A JP2009545662 A JP 2009545662A JP 2009545662 A JP2009545662 A JP 2009545662A JP 2010515748 A5 JP2010515748 A5 JP 2010515748A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- item
- cancer
- formula
- stem cell
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 claims description 55
- 239000000203 mixture Substances 0.000 claims description 29
- 108010028921 Lipopeptides Proteins 0.000 claims description 10
- 206010028980 Neoplasm Diseases 0.000 claims description 9
- 201000011510 cancer Diseases 0.000 claims description 9
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 9
- 210000000130 stem cell Anatomy 0.000 claims description 9
- 150000001875 compounds Chemical class 0.000 claims description 8
- 241000124008 Mammalia Species 0.000 claims description 7
- 125000001931 aliphatic group Chemical group 0.000 claims description 7
- 239000000718 radiation-protective agent Substances 0.000 claims description 7
- 210000003958 hematopoietic stem cell Anatomy 0.000 claims description 5
- 210000000265 leukocyte Anatomy 0.000 claims description 5
- 230000002093 peripheral effect Effects 0.000 claims description 5
- 208000019838 Blood disease Diseases 0.000 claims description 4
- 102000004127 Cytokines Human genes 0.000 claims description 4
- 108090000695 Cytokines Proteins 0.000 claims description 4
- 150000001413 amino acids Chemical class 0.000 claims description 4
- 208000014951 hematologic disease Diseases 0.000 claims description 4
- 208000018706 hematopoietic system disease Diseases 0.000 claims description 4
- 230000003211 malignant effect Effects 0.000 claims description 4
- 208000023275 Autoimmune disease Diseases 0.000 claims description 3
- 210000001185 bone marrow Anatomy 0.000 claims description 3
- 230000000694 effects Effects 0.000 claims description 3
- 206010006187 Breast cancer Diseases 0.000 claims description 2
- 208000026310 Breast neoplasm Diseases 0.000 claims description 2
- 206010010099 Combined immunodeficiency Diseases 0.000 claims description 2
- 201000004315 EAST syndrome Diseases 0.000 claims description 2
- 108010040721 Flagellin Proteins 0.000 claims description 2
- 206010025323 Lymphomas Diseases 0.000 claims description 2
- 206010029260 Neuroblastoma Diseases 0.000 claims description 2
- 206010033128 Ovarian cancer Diseases 0.000 claims description 2
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 2
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 2
- 208000024313 Testicular Neoplasms Diseases 0.000 claims description 2
- 206010057644 Testis cancer Diseases 0.000 claims description 2
- 208000002903 Thalassemia Diseases 0.000 claims description 2
- 102000004887 Transforming Growth Factor beta Human genes 0.000 claims description 2
- 108090001012 Transforming Growth Factor beta Proteins 0.000 claims description 2
- 208000016025 Waldenstroem macroglobulinemia Diseases 0.000 claims description 2
- 208000033559 Waldenström macroglobulinemia Diseases 0.000 claims description 2
- 208000007502 anemia Diseases 0.000 claims description 2
- 239000003963 antioxidant agent Substances 0.000 claims description 2
- 230000003078 antioxidant effect Effects 0.000 claims description 2
- 210000004027 cell Anatomy 0.000 claims description 2
- 201000010099 disease Diseases 0.000 claims description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 2
- 208000032839 leukemia Diseases 0.000 claims description 2
- 201000000050 myeloid neoplasm Diseases 0.000 claims description 2
- 229940124553 radioprotectant Drugs 0.000 claims description 2
- 208000007056 sickle cell anemia Diseases 0.000 claims description 2
- 238000006467 substitution reaction Methods 0.000 claims description 2
- 208000011580 syndromic disease Diseases 0.000 claims description 2
- 201000003120 testicular cancer Diseases 0.000 claims description 2
- 230000003537 radioprotector Effects 0.000 claims 2
- 239000002158 endotoxin Substances 0.000 claims 1
- 229920006008 lipopolysaccharide Polymers 0.000 claims 1
- 239000003814 drug Substances 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 description 4
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 4
- 210000004369 blood Anatomy 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 230000002159 abnormal effect Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 239000002576 chemokine receptor CXCR4 antagonist Substances 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- 229940121384 cxc chemokine receptor type 4 (cxcr4) antagonist Drugs 0.000 description 2
- YIQPUIGJQJDJOS-UHFFFAOYSA-N plerixafor Chemical compound C=1C=C(CN2CCNCCCNCCNCCC2)C=CC=1CN1CCCNCCNCCCNCC1 YIQPUIGJQJDJOS-UHFFFAOYSA-N 0.000 description 2
- 229960002169 plerixafor Drugs 0.000 description 2
- 208000018240 Bone Marrow Failure disease Diseases 0.000 description 1
- 206010065553 Bone marrow failure Diseases 0.000 description 1
- 208000031886 HIV Infections Diseases 0.000 description 1
- 208000037357 HIV infectious disease Diseases 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 238000010322 bone marrow transplantation Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 231100000572 poisoning Toxicity 0.000 description 1
- 230000000607 poisoning effect Effects 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US88416207P | 2007-01-09 | 2007-01-09 | |
| US60/884,162 | 2007-01-09 | ||
| US88989307P | 2007-02-14 | 2007-02-14 | |
| US60/889,893 | 2007-02-14 | ||
| US93856407P | 2007-05-17 | 2007-05-17 | |
| US60/938,564 | 2007-05-17 | ||
| US1324307P | 2007-12-12 | 2007-12-12 | |
| US61/013,243 | 2007-12-12 | ||
| PCT/US2008/050644 WO2008086426A2 (en) | 2007-01-09 | 2008-01-09 | Methods for increasing and mobilizing hematopoietic stem cells |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2010515748A JP2010515748A (ja) | 2010-05-13 |
| JP2010515748A5 true JP2010515748A5 (enExample) | 2012-02-09 |
| JP5389666B2 JP5389666B2 (ja) | 2014-01-15 |
Family
ID=39609361
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009545662A Expired - Fee Related JP5389666B2 (ja) | 2007-01-09 | 2008-01-09 | 造血幹細胞を増加および動員するための方法 |
Country Status (14)
| Country | Link |
|---|---|
| US (3) | US20100055077A1 (enExample) |
| EP (1) | EP2115124B1 (enExample) |
| JP (1) | JP5389666B2 (enExample) |
| KR (1) | KR101493474B1 (enExample) |
| CN (1) | CN101631850B (enExample) |
| BR (1) | BRPI0806557A2 (enExample) |
| CA (1) | CA2675032A1 (enExample) |
| EA (1) | EA018983B1 (enExample) |
| IL (1) | IL199766A (enExample) |
| MX (1) | MX2009007391A (enExample) |
| NZ (2) | NZ578928A (enExample) |
| SG (1) | SG177959A1 (enExample) |
| WO (1) | WO2008086426A2 (enExample) |
| ZA (1) | ZA200905378B (enExample) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2612102C (en) | 2005-06-13 | 2016-02-09 | Cleveland Biolabs, Inc. | Methods of protecting against apoptosis using lipopeptides |
| DK2032701T3 (da) * | 2006-06-23 | 2014-02-10 | Alethia Biotherapeutics Inc | Polynukleotider og polypeptider, der er inddraget i cancer |
| JP5781932B2 (ja) | 2008-11-03 | 2015-09-24 | アレシア・バイオセラピューティクス・インコーポレーテッド | 腫瘍抗原の生物活性を特異的にブロックする抗体 |
| US20130039882A1 (en) * | 2009-10-28 | 2013-02-14 | Henry Ford Health System | Method to mitigate injury from radiation exposure |
| EP2338521A1 (en) * | 2009-12-28 | 2011-06-29 | Helmholtz-Zentrum für Infektionsforschung GmbH | Lipopeptide- and lipoprotein-conjugates and its use |
| US20130230580A1 (en) * | 2010-09-14 | 2013-09-05 | Paul S. Frenette | Administration of SNS Neuroprotective Agents to Promote Hematopoietic Regeneration |
| EP2691421B1 (en) | 2011-03-31 | 2016-11-09 | Alethia Biotherapeutics Inc. | Antibodies against kidney associated antigen 1 and antigen binding fragments thereof |
| EA201992513A1 (ru) | 2012-01-09 | 2020-05-31 | Адс Терапьютикс Са | Способ лечения рака груди |
| WO2013149064A1 (en) * | 2012-03-30 | 2013-10-03 | University Of Pittsburgh-Of The Commonwealth System Of Higher Education | Uridine diphosphate compounds as mobilizers of hematopoietic progenitor cells |
| EP2838614B1 (en) | 2012-04-20 | 2019-09-11 | GB006, Inc. | Compositions for regulating integrins |
| CN104027791B (zh) * | 2013-03-06 | 2016-08-10 | 浙江海正药业股份有限公司 | 药物组合物 |
| JP2016518415A (ja) * | 2013-10-21 | 2016-06-23 | アドバンスド ニューロリジェネレイティブ セラピーズ エルエルシー | 加齢と疾患免疫機能障害と細胞老化とをリンパ球系幹細胞で修復する方法、及び治療使用のためのそれらの再適用する方法 |
| CN104744563B (zh) * | 2013-12-27 | 2019-02-26 | 中国人民解放军军事医学科学院毒物药物研究所 | 端基具有亲脂性结构的线性脂肽、其制备方法及用途 |
| WO2016073733A1 (en) * | 2014-11-06 | 2016-05-12 | Cleveland Biolabs, Inc. | Methods of treating cancer using lipopeptides |
| US20210189344A1 (en) * | 2018-08-30 | 2021-06-24 | The Regents Of The University Of California | Mobilization and collection of peripheral blood hematopoietic stem cells from deceased donors |
| CN112851755B (zh) * | 2021-01-13 | 2023-09-01 | 中国人民解放军军事科学院军事医学研究院 | 一种线性脂肽化合物及其制备方法与应用 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4554101A (en) | 1981-01-09 | 1985-11-19 | New York Blood Center, Inc. | Identification and preparation of epitopes on antigens and allergens on the basis of hydrophilicity |
| US5192553A (en) * | 1987-11-12 | 1993-03-09 | Biocyte Corporation | Isolation and preservation of fetal and neonatal hematopoietic stem and progenitor cells of the blood and methods of therapeutic use |
| DE19822820A1 (de) * | 1998-05-20 | 1999-11-25 | Biotechnolog Forschung Gmbh | Pharmazeutisches Präparat zur Wundbehandlung |
| CA2612102C (en) * | 2005-06-13 | 2016-02-09 | Cleveland Biolabs, Inc. | Methods of protecting against apoptosis using lipopeptides |
| CA2659337A1 (en) * | 2006-08-07 | 2008-02-14 | Genzyme Corporation | Combination therapy |
-
2008
- 2008-01-09 NZ NZ578928A patent/NZ578928A/xx not_active IP Right Cessation
- 2008-01-09 WO PCT/US2008/050644 patent/WO2008086426A2/en not_active Ceased
- 2008-01-09 EP EP08705809.5A patent/EP2115124B1/en not_active Not-in-force
- 2008-01-09 SG SG2012001392A patent/SG177959A1/en unknown
- 2008-01-09 CN CN2008800077612A patent/CN101631850B/zh not_active Expired - Fee Related
- 2008-01-09 KR KR20097016496A patent/KR101493474B1/ko not_active Expired - Fee Related
- 2008-01-09 EA EA200900806A patent/EA018983B1/ru not_active IP Right Cessation
- 2008-01-09 JP JP2009545662A patent/JP5389666B2/ja not_active Expired - Fee Related
- 2008-01-09 MX MX2009007391A patent/MX2009007391A/es active IP Right Grant
- 2008-01-09 BR BRPI0806557-8A2A patent/BRPI0806557A2/pt active Search and Examination
- 2008-01-09 CA CA002675032A patent/CA2675032A1/en not_active Abandoned
- 2008-01-09 US US12/522,606 patent/US20100055077A1/en not_active Abandoned
- 2008-01-09 NZ NZ603805A patent/NZ603805A/en not_active IP Right Cessation
-
2009
- 2009-07-08 IL IL199766A patent/IL199766A/en not_active IP Right Cessation
- 2009-07-31 ZA ZA200905378A patent/ZA200905378B/xx unknown
-
2013
- 2013-07-02 US US13/933,954 patent/US20140045747A1/en not_active Abandoned
-
2015
- 2015-03-04 US US14/638,888 patent/US20150174195A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2010515748A5 (enExample) | ||
| JP5389666B2 (ja) | 造血幹細胞を増加および動員するための方法 | |
| JP2022088551A (ja) | 増殖造血幹細胞／前駆細胞集団の利用 | |
| Ikeda et al. | Factors for PBPC collection efficiency and collection predictors | |
| US9567371B2 (en) | Short beta-defensin-derived peptides | |
| JP2005506317A5 (ja) | Ｇ−ｃｓｆ結合体 | |
| CN112135639B (zh) | 细胞组装介导的癌症免疫治疗检查点抑制剂的递送 | |
| Moog | Management strategies for poor peripheral blood stem cell mobilization | |
| RU2012121264A (ru) | Терапевтические пептиды | |
| KR20180041229A (ko) | 줄기 세포 이식을 위한 방법 | |
| KR20050093759A (ko) | 혈소판 및 조혈 줄기세포의 생산을 증가시키는 방법 | |
| US20140294755A1 (en) | Materials and Methods Relating to Stem Cell Mobilization by Multi-Pegylated Granulocyte Colony Stimulating Factor | |
| JPH10510842A (ja) | 造血細胞の増加方法 | |
| MXPA06000017A (es) | Combinacion farmaceutica de factor estimulador de colonias de granulocitos y factor de crecimiento placentario util para hemocitoblastos. | |
| AU2018378804A1 (en) | Dosing regimens for the mobilization of hematopoietic stem and progenitor cells | |
| WO2016180781A1 (en) | Combination therapy of mesothelioma | |
| Basser et al. | Rapid hematopoietic recovery after multicycle high-dose chemotherapy: enhancement of filgrastim-induced progenitor-cell mobilization by recombinant human stem-cell factor. | |
| CA2912366C (en) | Dextran sulfate for use in mobilization of cells | |
| KR20250161031A (ko) | 조혈 전구세포 동원 방법 | |
| Davies et al. | Plerixafor hydrochloride | |
| WO2023235715A2 (en) | Chimeric antigen receptor (car) t-cell adjuvant therapies | |
| EP3661561A1 (en) | Treating and inhibiting leukemia with nk-92 cells | |
| Varadi et al. | Conditioning regimens in autologous bone marrow transplantation | |
| EP4308694A1 (en) | Dosing regimens for hematopoietic stem cell mobilization for stem cell transplants in multiple myeloma patients | |
| Chari et al. | Feasibility of Cd34-positive stem cell mobilization by administration of AMD3100 six hours prior to leukapheresis |